MGMT and glioblastoma: Temozolomide (TMZ), the frontline chemotherapeutic agent for glioblastoma, frequently encounters resistance due to the upregulation of O6-methylguanine-DNA methyltransferase (MGMT), an enzyme that counteracts the alkylating effects of TMZ.